Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 4,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Not listed Phase 2 Interventional

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy

NCT03840057
View directory record Official record
Conditions
Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions
Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%
Drug
Lead sponsor
Waihong Chung
Other
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 18, 2026, 3:57 AM EDT
Active, not recruiting Phase 3 Interventional

Phase III Study of AK112 for NSCLC Patients

NCT06396065
View directory record Official record
Conditions
Non-Squamous Non-small Cell Lung Cancer
Interventions
AK112 Injection, Placebo Injection
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Bakersfield, California • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 4 Interventional

Rapydan Topical Anaesthesia for Arterial Cannulation

NCT01494311
View directory record Official record
Conditions
Arterial Catheterization
Interventions
Lidocaine/tetracaine patch, Placebo Patch, Subcutaneous injection of 0.5 ml Lidocain 1%, Subcutaneous injection of saline
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 18, 2026, 3:57 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial

NCT04115644
View directory record Official record
Conditions
Full Thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions
Ketorolac, Marcaine (placebo), Kenalog
Drug
Lead sponsor
Michael Khazzam
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 18, 2026, 3:57 AM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Not yet recruiting Phase 2 Interventional

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

NCT06103877
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD1163, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

NCT06637371
View directory record Official record
Conditions
Asthma
Interventions
AMG 691, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
15
States / cities
Lake Forest, California • Aventura, Florida • Palmetto Bay, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00691964
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ABT-874, etanercept, placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 18, 2026, 3:57 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

NCT05844293
View directory record Official record
Conditions
FXI
Interventions
FXI-GalNAc-siRNA, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Terminated Phase 1 Interventional

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

NCT01868360
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Subconjunctival aflibercept, Placebo: Standard of care only
Drug · Other
Lead sponsor
Balamurali Ambati
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

NCT02383498
View directory record Official record
Conditions
Chordoma
Interventions
Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
Other · Biological · Radiation + 1 more
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 18, 2026, 3:57 AM EDT
Not listed Phase 2 Interventional

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

NCT04197687
View directory record Official record
Conditions
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine
Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 1 Interventional

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

NCT01266616
View directory record Official record
Conditions
HIV Infections
Interventions
Profectus HIV MAG pDNA vaccine, IL-12, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery

NCT02734238
View directory record Official record
Conditions
Caloric Restriction, Exercise
Interventions
Sesame Oil, testosterone enanthate
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mifepristone and Mid-Trimester Termination of Pregnancy

NCT00382538
View directory record Official record
Conditions
Abortion, Induced, Abortion, Second Trimester
Interventions
Addition of mifepristone 200 mg 24 hours before induction
Drug
Lead sponsor
Boston University
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognitive, Emotional, and Neural Responses to Acute Inflammation

NCT03294564
View directory record Official record
Conditions
Healthy
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 18, 2026, 3:57 AM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
NNC0519-0130, Placebo, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

NCT03809663
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tezepelumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

NCT01149421
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Anaheim, California • Greenbrae, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 18, 2026, 3:57 AM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 3:57 AM EDT
Terminated Phase 4 Interventional Results available

RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain

NCT03305055
View directory record Official record
Conditions
Acute Pain, Wound Care, Posttraumatic Stress Disorder
Interventions
ketamine, Fentanyl
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 18, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Applying Num Vapocoolant Spray to Cervix Before Paracervical Block to Decrease Pain During Gynecology Procedures

NCT06227052
View directory record Official record
Conditions
Pain With Paracervical Block, Pain With Gynecology Procedure, Pain
Interventions
Num Vapocoolant Spray, Placebo
Device · Other
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 18, 2026, 3:57 AM EDT